Amber Implants VCFix Granted FDA Breakthrough Designation

Amber Implants VCFix Spinal Implant

Amber Implants was granted Breakthrough Device Designation by FDA for its VCFix® spinal system, which aims to improve the treatment of vertebral fractures.

A first-In-human clinical trial is expected to commence in early 2022 in Europe and the U.S.

VCFix spinal system is the first solution to treat vertebral fractures that does not rely on...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us